Kalaris Therapeutics, Inc.

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Operating primarily out of Australia, Opthea Limited is a clinical-stage biopharmaceutical firm dedicated to developing and marketing treatments for ophthalmic conditions. Its therapeutic pipeline leverages a robust intellectual property portfolio centered on Vascular Endothelial Growth Factors (VEGF) such as VEGF-C and VEGF-D, along with VEGF Receptor-3. This scientific foundation aims to address disorders characterized by abnormal blood and lymphatic vessel formation and excessive vascular leakage. The company's flagship product, OPT 302, is currently undergoing clinical trials. This soluble form of VEGFR-3 is being explored as a groundbreaking treatment for both wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Notably, OPT 302 functions as a novel VEGF-C/D inhibitor, intended to be administered alongside existing VEGF-A inhibitors to combat wet AMD and various other retinal disorders. Initially incorporated in 1984 as Circadian Technologies Limited, the company officially adopted the name Opthea Limited in December 2015. Its corporate headquarters are located in South Yarra, Australia.

Character BiosciencesBiotechUnited States

68% match

Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.

Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.

AlkeusBiotechUnited States

68% match

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.